madopar cr capsules
roche products ltd - benserazide hydrochloride; levodopa - modified-release capsule - 25mg ; 100mg
madopar 50mg/12.5mg capsules
roche products ltd - benserazide hydrochloride; levodopa - oral capsule - 12.5mg ; 50mg
madopar 200mg/50mg capsules
roche products ltd - benserazide hydrochloride; levodopa - oral capsule - 50mg ; 200mg
madopar 50mg/12.5mg dispersible tablets
roche products ltd - benserazide hydrochloride; levodopa - dispersible tablet - 12.5mg ; 50mg
madopar 100mg/25mg dispersible tablets
roche products ltd - benserazide hydrochloride; levodopa - dispersible tablet - 25mg ; 100mg
madopar 100/25 milligram tablets
roche products limited - levodopa, benserazide hydrochloride - tablets - 100/25 milligram - dopa and dopa derivatives
madopar 200/50 milligram capsules hard
roche products limited - levodopa, benserazide hydrochloride - capsules hard - 200/50 milligram - dopa and dopa derivatives
madopar 50/12.5 milligram tablets
roche products limited - levodopa, benserazide hydrochloride - tablets - 50/12.5 milligram - dopa and dopa derivatives
madopar 100mg/25mg capsules
roche products ltd - levodopa; benserazide hydrochloride - oral capsule - 100mg ; 25mg
madopar
roche products (nz) ltd - benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base; levodopa 200mg; - capsule - 250 mg - active: benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base levodopa 200mg excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.